GHK-Cu at the skin surface
Copper chemistry and matrix synthesis make a compelling pair. Getting the preparation through intact skin is part of the practical difficulty.
GHK in plasma
GHK was isolated from human plasma in 1973 by Loren Pickart, as a factor that prompted aged liver tissue to synthesise proteins more like younger tissue. The skin-regeneration review traces that history into repair and matrix biology. It is a stranger and more interesting beginning than a generic anti-aging claim.
GHK is glycine, histidine and lysine; GHK-Cu binds that tripeptide to a copper(II) ion. The GHK sequence also occurs in collagen and in SPARC/osteonectin. The same review describes the copper complex stimulating collagen, elastin, glycosaminoglycans and decorin in dermal fibroblast cell cultures. The specificity of that supporting material is appealing: repair needs an environment in which cells can live and move.
Skin penetration
A 2025 review of topical GHK identifies poor permeability through the stratum corneum as a central difficulty. Free GHK’s clogP is -2.24, reflecting its affinity for water. Work on palmitoylation and other delivery strategies tries to change that practical limitation.
The human skin penetration experiment measured copper delivery through dermatomized skin outside the body and a dermal copper depot over 48 hours. That preparation and that measured substance matter. The result describes copper in an ex vivo skin experiment; it cannot establish whole-body rejuvenation. Careful skin-layer measurements get my vote over expansive longevity slogans.
Human skin and hair results
The 2015 review of skin regeneration reports increased collagen production in 70% of GHK-Cu-treated women, compared with 50% for vitamin C and 40% for retinoic acid, alongside small topical studies of skin laxity, fine lines and wrinkle depth. Those are local findings from a limited clinical record.
The 6-month trial in 45 men with male-pattern hair loss tested a combination of 5-aminolevulinic acid and GHK peptide. Hair-count increases were 52.6 at 100 mg/mL and 71.5 at 50 mg/mL, versus 9.6 for placebo, with no adverse events reported in any group. This used a combination containing GHK, so it leaves the individual contribution of GHK-Cu unresolved. The distinction is frustrating only if one starts with a claim that the trial never set out to test.
Gene expression
The 2018 gene-data analysis reports changes in about 31.2% of human genes at a 50%-or-greater expression-change threshold, with about 59% of affected genes increasing and 41% decreasing. The work includes protein-quality-control, DNA-repair and antioxidant pathways. These are database and gene-expression findings.
The familiar “about 4,000 genes” claim uses a broader extrapolation; the count at the stated threshold is on the order of 2,100. My enthusiasm drops when the dramatic total loses its threshold. Protein-level and in vivo validation would clarify what those shifts accomplish. A substantial share of the foundational literature also comes from one investigator and colleagues.
Cosmetic history
Topical copper tripeptide-1 is a legal cosmetic ingredient with a long history of use. There is no FDA- or EMA-approved therapeutic GHK-Cu product, and validated human pharmacokinetic data for systemic or injectable GHK-Cu are absent. The topical review gives a useful boundary around the skin findings. Compounded injectable access requires a prescription after a licensed provider’s review and decision; research-labelled products also remain available.
The documented cautions include localised pigmentation changes and formulation incompatibility with vitamin C and low-pH acids. Copper-balance concerns with prolonged systemic use remain theoretical; the published record described here contains no human copper-toxicity cases attributed to GHK-Cu. None of that turns a topical cosmetic history into established systemic safety. KPV, another tripeptide, takes this discussion toward inflammatory signalling in a very different experimental setting.